Pivotal study supports belzutifan approval for patients with advanced kidney cancer
The LITESPARK-005 phase 3 clinical trial enrolled 746 patients with metastatic clear cell renal cell…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Small molecules, big impact: advancing immune checkpoint inhibitors for cancer
Recent research highlights an approach in cancer therapy with small molecule drugs targeting immune checkpoints.…
Immune cells have a metabolic backup plan for accessing their anti-cancer playbook
Immune cells use two different routes to produce acetyl-CoA, an essential metabolite required to fight…
Tumour cell–coated carbon nanohorn tested for efficient delivery of drugs in cancer therapy
Cancer remains one of the most challenging diseases to treat due to its complexity and…
Promising treatment for rectal cancer confirmed in major study
A new treatment for locally advanced rectal cancer shows favourable results in that surgery can…
Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying…
Detective algorithm predicts best drugs for genetic disorders and cancer
A computational model built by researchers at the Institute of Research in Biomedicine (IRB Barcelona)…
New anti-CKAP4 antibodies deliver hope for pancreatic cancer treatment
Pancreatic cancer is an aggressive disease with few available treatments. Thankfully, researchers are hard at…
Precision therapy for metastatic prostate cancer improves survival
Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer…
Unlocking the potential of targeted therapies for multiple myeloma
Multiple myeloma (MM) is a complex haematological malignancy with significant unmet needs. While conventional therapies…